98%
921
2 minutes
20
Advances in imaging, pharmacological, and procedural technologies have rapidly expanded the care of pulmonary embolism. Earlier, more accurate identification and quantification has enhanced risk stratification across the spectrum of the disease process, with a number of clinical tools available to prognosticate outcomes and guide treatment. Direct oral anticoagulants have enabled a consistent and more convenient long-term therapeutic option, with a greater shift toward outpatient treatment for a select group of low-risk patients. The array of catheter-directed therapies now available has contributed to a more versatile and nuanced armamentarium of treatment options, including ultrasound-facilitated thrombolysis and mechanical thrombectomy. Research into supportive care for pulmonary embolism have explored the optimal use of vasopressors and volume resuscitation, as well as utilization of various devices, including right ventricular mechanical support and extracorporeal membrane oxygenation. Even in the realm of surgery, outcomes have steadily improved in experienced centers. This rapid expansion in diagnostic and therapeutic data has necessitated implementation of pulmonary embolism response teams to better interpret the available evidence, manage the utilization of advanced therapies, and coordinate multidisciplinary care. We provide a narrative review of the risk stratification and management of pulmonary embolism, with a focus on structuralizing the multidisciplinary approach and organizing the literature on new and emerging therapies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11728314 | PMC |
http://dx.doi.org/10.3390/jcm13247637 | DOI Listing |
Eur J Case Rep Intern Med
August 2025
Internal Medicine, University of California, Riverside School of Medicine, Riverside, USA.
Introduction: Pulmonary embolism (PE) is a life-threatening condition with well-defined management strategies; however, the presence of a clot-in-transit (CIT)-a mobile thrombus within the right heart-introduces a uniquely high-risk scenario associated with a significantly elevated mortality rate. While several therapeutic approaches are available-including anticoagulation, systemic thrombolysis, surgical embolectomy, and catheter-directed therapies-there is no established consensus on a superior treatment modality. Catheter-based mechanical thrombectomy has emerged as a promising, minimally invasive alternative that mitigates the bleeding risks of systemic thrombolysis and the invasiveness of surgery.
View Article and Find Full Text PDFCureus
August 2025
Respiratory Medicine, Sri Ramachandra Institute of Higher Education and Research, Chennai, IND.
Tuberculosis (TB) is a multisystem infectious disease with both pulmonary and extrapulmonary manifestations. TB can also induce a hypercoagulable state, setting off a cascade of changes in the body, including systemic inflammation, endothelial dysfunction, and abnormalities in the coagulation and fibrinolytic pathways. Collectively, these factors significantly increase the risk of venous thromboembolism, such as deep vein thrombosis and pulmonary embolism.
View Article and Find Full Text PDFAnat Cell Biol
September 2025
Department of Anatomy, All India Institute of Medical Sciences Bibinagar, Hyderabad, India.
We present a rare anatomical variation of the deep femoral vein (DFV) originating from the popliteal vein (PV) with an associated aneurysm. The DFV arose from the PV at the adductor hiatus, exhibited an aneurysm, and coursed upward through the fourth osseo-aponeurotic opening of the adductor magnus muscle to enter the anterior thigh compartment before draining into the femoral vein. This unique variation likely resulted from developmental deviations during intrauterine life.
View Article and Find Full Text PDFJACC Adv
September 2025
Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA. Electronic address: